Jack brings his expertise for clinical trial development, execution and analysis to his role as Medical Monitor and Medical Safety Reviewer for our EU studies. In addition, he serves to harmonize our global experience and enrollment history for all of our studies to provide real-time metrics along with medical and scientific considerations.
Dr. Welch joined Theradex Oncology in 2019 after a decade at the US National Cancer Institute. At the NCI, Dr. Welch was head of the GI, Thoracic, and Rare Cancers portfolio within the Cancer Therapy Evaluation Program. He was also a senior investigator at the NCI Center for Global Health, where he promoted international clinical trial collaborations. Previously, he served as a senior clinical research physician at the European Organization for Research and Treatment of Cancer (EORTC).
Jack was trained in Experimental Therapeutics at Roswell Park Cancer Institute, with a PhD in pharmacology. His medical specialty is pediatric hematology-oncology, with fellowship training at Children’s Hospital of Philadelphia. Jack’s research background includes molecular and computational biology.